Journal of Diabetes Research

Research Article

Association between Circulating Ectodysplasin A and Diabetic Kidney Disease

Table 1

Baseline clinical characteristics of all patients.
CharacteristicsControl ()T2DM () value
Sex, men (%)27 (45.8%)104 (55.0%)0.214
Age, y<0.001
BMI (kg/m2)23.20 (21.30, 25.39)25.17 (22.93, 27.35)<0.001
WC (cm)<0.001
HC (cm)96.00 (92.20, 100.50)96.00 (92.00, 100.50)0.805
WHR0.87 (0.82, 0.92)0.94 (0.90, 0.97)<0.001
Duration of T2DM (M)—48.00 (1.00, 126.00)—
Hypertension, (%)4 (6.8%)90 (47.6%)<0.001
SBP (mmHg)118.00 (106.00, 126.00)132 (122.00, 146.00)<0.001
DBP (mmHg)68.00 (61.00, 78.00)81.00 (75.00, 89.00)<0.001
Smoking, (%)15 (25.4%)45 (23.8%)0.801
ACEI/ARB use—59 (31.2%)—
Statins use—4 (2.1%)—
Insulin—57 (30.2%)—
Oral agents—65 (34.4%)—
Insulin+oral agents—31 (16.4%)—
FPG (mmol/L)4.60 (4.26, 5.04)9.95 (7.94, 12.76)<0.001
2hPG (mmol/L)6.36 (5.77, 6.91)19.05 (15.91, 22.90)<0.001
FIns (μIU/mL)4.62 (2.73, 6.56)7.41 (4.60, 11.84)<0.001
2hIns (μIU/mL)26.99 (18.58, 43.56)28.30 (16.47, 52.38)0.577
FC-P (ng/mL)0.058
2hCP(ng/mL)7.78 (5.75, 9.64)4.62 (3.11, 6.78)<0.001
Hb1Ac (%)5.70 (5.60, 5.90)9.30 (8.05, 11.00)<0.001
HOMA-IR0.95 (0.56, 1.35)3.53 (2.17, 4.93)<0.001
HOMA-β77.02 (46.49, 135.73)22.70 (11.82, 45.22)<0.001
TG (mmol/L)1.30 (0.90, 1.77)1.93 (1.36, 2.98)<0.001
TC (mmol/L)4.92 (4.50, 5.51)4.94 (4.21, 5.91)0.673
LDL-C (mmol/L)2.66 (2.34, 3.30)2.81 (2.33, 3.65)0.229
HDL-C (mmol/L)1.41 (1.19, 1.69)1.07 (0.90, 1.27)<0.001
ALT (U/L)15.40 (9.80, 28.90)22.00 (13.55, 38.05)0.014
AST (U/L)17.10 (13.70, 21.60)17.40 (12.95, 26.50)0.998
UA (μmol/L)0.325
BUN (mmol/L)4.70 (4.14, 5.83)5.19 (4.33, 6.08)0.045
Creatinine (μmol/L)66 (58.80, 75.20)57.80 (47.95, 69.45)0.001
eGFR(mL/[min1.73m2])103.20 (92.50, 111.60)110.57 (96.15, 126.20)0.030
EDA268.72 (218.31, 331.61)337.47263.89, 407.00)<0.001